ArTS Archivio della ricerca di Trieste

ROCCA, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.882
NA - Nord America 2.298
EU - Europa 1.263
SA - Sud America 525
AF - Africa 75
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 1
Totale 7.049
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.200
SG - Singapore 1.069
CN - Cina 597
IT - Italia 450
BR - Brasile 399
HK - Hong Kong 358
VN - Vietnam 289
KR - Corea 238
DE - Germania 112
FR - Francia 109
NL - Olanda 90
IN - India 87
SE - Svezia 81
RU - Federazione Russa 70
CH - Svizzera 69
GB - Regno Unito 65
PL - Polonia 57
CA - Canada 45
FI - Finlandia 42
AR - Argentina 40
BD - Bangladesh 38
MX - Messico 32
TW - Taiwan 32
ID - Indonesia 24
IE - Irlanda 24
EC - Ecuador 22
MA - Marocco 22
AT - Austria 20
IQ - Iraq 18
TR - Turchia 18
CO - Colombia 17
CL - Cile 16
AE - Emirati Arabi Uniti 14
PH - Filippine 14
JP - Giappone 13
UA - Ucraina 13
PK - Pakistan 12
PY - Paraguay 12
ES - Italia 11
SA - Arabia Saudita 10
UZ - Uzbekistan 9
EG - Egitto 8
IR - Iran 8
KE - Kenya 8
RO - Romania 8
SN - Senegal 8
TH - Thailandia 8
VE - Venezuela 8
BE - Belgio 7
UY - Uruguay 7
ZA - Sudafrica 7
BG - Bulgaria 6
DZ - Algeria 6
TT - Trinidad e Tobago 6
CZ - Repubblica Ceca 4
JM - Giamaica 4
XK - ???statistics.table.value.countryCode.XK??? 4
AZ - Azerbaigian 3
BO - Bolivia 3
GE - Georgia 3
GR - Grecia 3
GT - Guatemala 3
HU - Ungheria 3
IL - Israele 3
JO - Giordania 3
LT - Lituania 3
NO - Norvegia 3
PT - Portogallo 3
SI - Slovenia 3
TN - Tunisia 3
AL - Albania 2
CI - Costa d'Avorio 2
ET - Etiopia 2
MY - Malesia 2
NI - Nicaragua 2
NP - Nepal 2
PA - Panama 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
AU - Australia 1
BF - Burkina Faso 1
BH - Bahrain 1
BS - Bahamas 1
CM - Camerun 1
CR - Costa Rica 1
DK - Danimarca 1
DM - Dominica 1
GA - Gabon 1
HN - Honduras 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LY - Libia 1
MR - Mauritania 1
MT - Malta 1
NG - Nigeria 1
Totale 7.042
Salva come PNG Salva come JPEG
Città #
Singapore 593
Ashburn 356
Hong Kong 353
San Jose 321
Hefei 247
Seoul 234
Boardman 157
Beijing 151
Ho Chi Minh City 99
Dallas 98
Trieste 86
Council Bluffs 82
Santa Clara 80
Milan 67
Chicago 60
Bern 59
Hanoi 57
Los Angeles 57
Lauterbourg 54
Columbus 48
São Paulo 46
New York 40
Zgierz 38
The Dalles 33
Princeton 32
Moscow 31
Buffalo 30
Frankfurt am Main 28
Taipei 27
London 26
Dublin 24
Helsinki 22
North Bergen 22
Pune 21
Rome 21
Seattle 21
Nuremberg 20
Memphis 18
Houston 17
Redondo Beach 17
Atlanta 16
Düsseldorf 15
Fairfield 15
Lappeenranta 15
Munich 15
Orem 15
Rio de Janeiro 15
Boydton 14
Amsterdam 13
Shanghai 13
Chennai 12
Miano 12
Warsaw 12
Quito 11
Stockholm 11
Tappahannock 11
Brasília 10
Casablanca 10
Chandler 10
Montreal 10
Toronto 10
Treviso 10
Denver 9
Dhaka 9
Haiphong 9
Hangzhou 9
Vienna 9
Wilmington 9
Woodbridge 9
Ankara 8
Dakar 8
San Donà di Piave 8
Santiago 8
Tashkent 8
Bologna 7
Brussels 7
Da Nang 7
Jacksonville 7
Jakarta 7
Phoenix 7
Apodaca 6
Asunción 6
Biên Hòa 6
Can Tho 6
Duino-Aurisina 6
Itaquaquecetuba 6
Shenzhen 6
Tokyo 6
Torviscosa 6
Ann Arbor 5
Belo Horizonte 5
Brooklyn 5
Cambridge 5
Dubai 5
Fortaleza 5
Hải Dương 5
Kingston 5
Lahore 5
L’Aquila 5
Madrid 5
Totale 4.322
Salva come PNG Salva come JPEG
Nome #
Complement protein C1q stimulates hyaluronic acid degradation via gC1qR/HABP1/p32 in malignant pleural mesothelioma 195
Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial 188
A tailored machine learning approach for mortality prediction in severe COVID-19 treated with glucocorticoids 183
Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report 179
179 C1q stimulates hyaluronic acid degradation via gC1qR/HABP1/p32 in malignant pleural mesothelioma 177
Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT 164
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer 150
Ribociclib and Endocrine Therapy in Breast Cancer 122
The Predictive and Prognostic Role of RAS-RAF-MEK-ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets 119
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 108
Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis 107
Can Systems Biology Advance Clinical Precision Oncology? 105
CD99 Expression and Prognostic Impact in Glioblastoma: A Single-Center Cohort Study 103
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab 99
A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study 96
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer 95
A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer 92
Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study 91
Single-Cell NGS-Based Analysis of Copy Number Alterations Reveals New Insights in Circulating Tumor Cells Persistence in Early-Stage Breast Cancer 91
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 90
Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? 90
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer? 88
Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ 86
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer 85
Androgen receptor signaling pathways as a target for breast cancer treatment 85
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial 85
Identifying the best treatment choice for relapsing/refractory glioblastoma: a systematic review with multiple Bayesian network meta-analyses 84
Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapy 84
A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemo-immunotherapy in patients with advanced melanoma 84
Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer? 83
Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial 83
Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression 83
Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer 83
A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer 81
Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype 80
A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy 80
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 79
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial 79
Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer 79
Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter 79
Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience 78
Precision medicine: PI3K targeting in advanced breast cancer 77
Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas 77
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer? 77
A phase II study of primary dose-dense sequential doxorubicin plus cyclophosphamide and docetaxel in cT4 breast cancer 76
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 76
A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer 75
WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis 75
HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer 73
Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report 72
Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population? 71
[Prophylaxis of toxic effects on the peripheral venous system associated with intravenous administration of vinorelbine] 71
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels 71
Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial 70
Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer. A case report 69
Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy 66
Double-blind, multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients with cancer 64
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer 63
Early C-reactive protein reduction predicts survival in COVID-19 severe pneumonia treated with glucocorticoids 62
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer 61
Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients 60
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer 56
The dynamics of tumour-vasculature interaction suggests low-dose, time-dense anti-angiogenic schedulings 50
Multicentric/multifocal breast cancer with a single histotype: is the biological characterization of all individual foci justified? 47
Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients 46
CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience 42
Oxaliplatin combined with 5-fluorouracil and methotrexate in advanced colorectal cancer 42
Transcriptomic profiling of circulating tumor cells from metastatic breast cancer patients reveals new hints in their biological features and phenotypic heterogeneity 41
Existence and relevance of fulminant severe community-acquired pneumonia 38
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel 37
Refining treatment strategies for non-small cell lung cancer lacking actionable mutations: insights from multi-omics studies 37
Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence 36
Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients 34
Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer 34
Virtual Biomarkers and Simplified Metrics in the Modeling of Breast Cancer Neoadjuvant Therapy: A Proof-of-Concept Case Study Based on Diagnostic Imaging 33
Circulating tumor cells in early breast cancer: A connection with vascular invasion 33
Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer 31
Association between hepatitis C virus and non-Hodgkin's lymphoma, and effects of viral infection on histologic subtype and clinical course 31
Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer 30
Radiotherapy, morphine, and bone pain: a difficult relationship? 30
Reliability of Left Ventricular Ejection Fraction from Three-Dimensional Echocardiography for Cardiotoxicity Onset Detection in Patients with Breast Cancer 30
Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer 29
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer 29
CTCs in early breast cancer: A path worth taking 28
Hyperfractionated radiotherapy in locally advanced nasopharyngeal cancer. An analysis of 43 consecutive patients 27
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines  for the adjuvant treatment of early breast cancer? 25
Diagnosis and management of neck metastases from an unknown primary 25
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects 25
Investigating biochemical markers of Acupuncture's effectiveness in managing climacteric syndrome in breast cancer patients: the FLAIR study 25
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer 25
Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy 24
Update: current management issues in malignant melanoma 24
Postoperative hyperprolactinemia could predict longer disease-free and overall survival in node-negative breast cancer patients 24
Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy 24
Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy 23
Breast cancer vaccines: a clinical reality or fairy tale? 22
Paraneoplastic hypocalcemia-induced heart failure in advanced breast cancer: A case report and literature review 22
Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents 22
The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer 22
Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study 20
Totale 6.921
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.014
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.014
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 0 0 0 0 1 1
2021/202251 1 0 0 0 0 1 0 2 1 14 3 29
2022/2023470 16 2 9 19 32 65 2 100 101 8 95 21
2023/2024701 89 43 32 63 63 54 92 112 20 35 65 33
2024/20251.950 19 167 308 104 157 114 226 88 265 172 121 209
2025/20264.030 401 483 317 304 259 273 493 120 506 682 192 0
Totale 7.280